Navigation Links
One-Year European Registry Data Released for Popliteal Stenting With SUPERA®
Date:2/8/2011

LEIPZIG, Germany, Feb. 8, 2011 /PRNewswire/ -- Data from the Leipzig Registry tracking the results of patients treated with the SUPERA® stent for peripheral arterial disease (PAD) of the popliteal artery were reported during the recent 2011 Leipzig Interventional Course (LINC).  The SUPERA stent is CE marked for biliary and peripheral vascular use in Europe.  In the United States the SUPERA stent is the subject of an ongoing FDA-approved IDE trial called SUPERB (Comparison of the SUPERA PERipheral System to a Performance Goal Derived from Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery) for treatment of PAD of the superficial femoral artery (SFA).

Dr. Andrej Schmidt of the Department of Angiology at Park Hospital and Heart Center in Leipzig presented the 12-month European data.  The 101 patients treated at Park Hospital had advanced PAD.  Nearly a third of the patients were classified as Rutherford 4 or 5, and almost 50 percent had an occlusion of the popliteal artery.  The average stent length within the registry was approximately 8.5 centimeters.

The primary patency rate, measured by duplex ultrasonography, was 87 percent at 12 months.  In addition, there were no stent fractures detected by x-ray at an average of 13.3 months.

"The SUPERA stent has become our stent of choice," commented Dr. Schmidt.  "No standard nitinol stent provides the same level of flexibility and radial strength, and both characteristics are necessary to conform to and support the SFA and popliteal anatomy."

"SUPERA is a different class of stent, and is exhibiting remarkable long-term durability in extremely diseased patients," commented Richard C. Kovach, M.D. and Chair, Department of Endovascular Medicine and Director, Cardiac Catheterization Laboratory at Deborah Heart and Lung Center in Browns Mills, New Jersey.  "There were several presentations and live cases throughout LINC highlighting ho
'/>"/>

SOURCE IDEV Technologies, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
4. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
5. New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohns Disease
6. Diabetes Conversation Map(TM) Education Tools Celebrate One-Year Anniversary
7. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
10. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
11. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... April 24, 2015  Blueprint Medicines today announced ... and potent inhibitor of fibroblast growth factor receptor ... of hepatocellular carcinoma (HCC) that are dependent on ... induced complete tumor regression in a subset of ... at the highest dose levels. These data will ...
(Date:4/23/2015)... S.C. , April 23, 2015 Once ... and strengthening our commitment to patient safety. ... the fight against infectious disease. The next ... Medical gas sensors are now mounted in the ... the need to open ceiling tiles potentially releasing dust ...
(Date:4/23/2015)... 2015  Research Solutions, Inc. (OTCQB: RSSS), a pioneer in ... information for life science companies, academic institutions, and other ... the 16 th Annual B. Riley & Co. ... the Loews Hollywood Hotel in ... management is scheduled to present on Tuesday, May 12 ...
Breaking Medicine Technology:Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3BeaconMedaes launches new Zone Valve Box Assembly 2Research Solutions to Present at the 16th Annual B. Riley & Co. Investor Conference on May 12, 2015 2Research Solutions to Present at the 16th Annual B. Riley & Co. Investor Conference on May 12, 2015 3
... Jan. 23, 2012  B. Braun Medical Inc. (B. Braun), a ... received U.S. Food and Drug Administration (FDA) approval for ... B. Braun,s DUPLEX® Drug Delivery System . The ... an FDA-approved 2g Cefazolin dose to hospitals and other healthcare ...
... Jan. 23, 2012 ThermoGenesis Corp. (NASDAQ: KOOL ... process and store adult stem cells, said today, it had ... from a new public cord blood bank that will begin ... Services, a national charitable organization that manages the supply of ...
Cached Medicine Technology:B. Braun Becomes the First to Deliver FDA-Approved 2g Cefazolin 2B. Braun Becomes the First to Deliver FDA-Approved 2g Cefazolin 3Canada's First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System 2Canada's First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System 3Canada's First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System 4
(Date:4/24/2015)... 2015 Anchor Health Administrators (Anchor), specialists ... today announced their exclusive agreement with LTC Solutions for ... Insurance distribution partner. , Anchor has more than 18 ... benefits for associations, and is currently the designated advocate ... Term Care Insurance member benefit. , “I am very ...
(Date:4/24/2015)... Olive Fertility Centre is proud to ... co-director, has been honoured for his pioneering work in ... Hope Gala. , “We are very pleased to ... has been at the forefront of fertility research and ... Executive Director of Fertile Futures--a Canadian non-profit organization that ...
(Date:4/24/2015)... With years of experience providing consumer ... to be partnered with a veterinary college where veterinary ... This partnership has brought new payment options for families ... providing an in-house payment plan for many years, the ... to increase financing options available to avoid having to ...
(Date:4/24/2015)... National Access Cannabis (NAC), ... to medical cannabis, is taking a leadership role in ... patients. , NAC is the first to back mdBriefCase ... grant, NAC will be providing 300 healthcare professionals with ... to help Canadians gain safe and responsible access to ...
(Date:4/24/2015)... Opera ” was featured on NewsWatch as part of its ... products available to consumers. Andrew Tropeano, a technology expert and ... viewers how this is the fastest way to surf the ... be in existence. But each web browser is slightly different ... Celebrating their 20th anniversary this year, Opera connects over 350 ...
Breaking Medicine News(10 mins):Health News:Olive Fertility Centre Co-founder, Dr Al Yuzpe, Recognized as a Pioneer in Fertility Preservation 2Health News:University of Missouri Veterinary Medical Teaching Hospital Teams with UGA 2Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2Health News:A Web Browser That Connects over 350 Million People was Featured on NewsWatch Television 2
... ValueOptions(R), Inc., the nation,s largest independent behavioral ... entered into an agreement with CareIntegra to provide ... its core product offerings. (Logo: ... CareIntegra and ValueOptions(R) will collaborate to develop and ...
... Va., Jan. 7 CEL-SCI Corporation (NYSE Alternext ... announced today the initiation of a definitive study of ... the long-lasting beneficial effects on animals with the disease. ... a large pharmaceutical company which is evaluating the possibility ...
... ORLEANS, Jan. 7 Jones Walker is pleased to announce ... an Order of the British Crown that has been in ... in the New Orleans office of Jones Walker, was recently ... Hamilton, a Partner in the firm,s Mobile and Washington offices, ...
... Virginia, January 7 Ekahau Inc., a leading,provider ... announced,that after a competitive bid process it was ... to provide the Ekahau Real Time,Location System (RTLS) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081014/324879-a ) , ...
... shownOAKBROOK TERRACE, Ill., Jan. 7 Even though nurses ... study published in the January 2009 issue of ... shows that nurses often are not included when ... such a hands-on role at the bedside of their ...
... Atlanta-based Billian Publishing, Inc.,owners of Billian,s HealthDATA, announced ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070925/BILLIANSLOGO ) ... founded in 1989 just as the information technology,industry ... Since then, new,and established companies have contracted with ...
Cached Medicine News:Health News:ValueOptions(R) Enters Agreement with CareIntegra to Provide Integrated Health Services 2Health News:CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine 2Health News:CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine 3Health News:Jones Walker Attorneys Named to Positions in Order of British Crown 2Health News:Ekahau Selected to Provide RTLS to University HealthSystem Consortium 2Health News:Ekahau Selected to Provide RTLS to University HealthSystem Consortium 3Health News:Study Finds Failure to Include Nurses in Process of Admitting Errors to Patients, Families 2Health News:Study Finds Failure to Include Nurses in Process of Admitting Errors to Patients, Families 3Health News:Billian Publishing, Inc. Announces Acquisition of Porter Research 2
The Oculus easyfield is an exciting new compact perimeter to do automatic static perimetry up to 30 degrees eccentricity. It has been designed for the combined use as a visual field screener and peri...
Automatic tangent screen with plane type central field tester. Static, quantitative perimetry....
Focus Dailies Toric are the first daily disposable lens for astigmatism...
Frequency 55 Toric XR is a great option for those with high levels of astigmatism...
Medicine Products: